These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26591651)

  • 1. Androgen deprivation therapy and cardiovascular risk.
    Rees J
    Practitioner; 2015 Sep; 259(1785):5. PubMed ID: 26591651
    [No Abstract]   [Full Text] [Related]  

  • 2. Hormonal treatment of prostate cancer.
    Garnick MB
    N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
    [No Abstract]   [Full Text] [Related]  

  • 3. [Total androgen blockade].
    Namiki M; Mizokami A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate].
    Boccon-Gibod L
    Prog Urol; 1997 Feb; 7(1):97-8. PubMed ID: 9116748
    [No Abstract]   [Full Text] [Related]  

  • 5. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
    Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
    BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Clandestine' prostate cancer haunts.
    Chapman B
    CAP Today; 1996 Feb; 10(2):1, 34-6, 38 passim. PubMed ID: 10160261
    [No Abstract]   [Full Text] [Related]  

  • 8. Nonsteroidal anti-androgens: role in treating advanced prostate cancer.
    Newton M; Kosier JH
    Urol Nurs; 1998 Mar; 18(1):56-7, 83. PubMed ID: 9582897
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.
    Malik R; Jani AB; Liauw SL
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1022-8. PubMed ID: 20510547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
    Greiman AK; Keane TE
    Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced prostate cancer. Hormonal treatment.
    de la Haba-Rodríguez J
    Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
    [No Abstract]   [Full Text] [Related]  

  • 12. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
    Kittai AS; Blank J; Graff JN
    Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversies surrounding hormonal deprivation.
    Denis LJ
    Acta Urol Belg; 1996 May; 64(2):81-4. PubMed ID: 8701819
    [No Abstract]   [Full Text] [Related]  

  • 14. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of neoadjuvant therapy for prostate cancer].
    Okada K; Hachiya T
    Nihon Hinyokika Gakkai Zasshi; 1997 Sep; 88(9):769-77. PubMed ID: 9364842
    [No Abstract]   [Full Text] [Related]  

  • 16. Researchers probe consequences of androgen deprivation for prostate cancer.
    Friedrich MJ
    JAMA; 2006 Nov; 296(19):2305-6. PubMed ID: 17105787
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Pitts WR
    J Urol; 2003 Dec; 170(6 Pt 1):2392-3; author reply 2393-4. PubMed ID: 14634434
    [No Abstract]   [Full Text] [Related]  

  • 18. Choosing a prostate cancer drug.
    Baker H
    Br J Nurs; 2014 Sep 11-24; 23(16):S14, S16. PubMed ID: 25203849
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapy and prostate cancer.
    Dacker R
    Radiol Technol; 1997; 68(3):194-5. PubMed ID: 9008013
    [No Abstract]   [Full Text] [Related]  

  • 20. Complete hormonal blockage--antiandrogens.
    Bierkens AF; Debruyne FM
    Acta Urol Belg; 1996 May; 64(2):77-9. PubMed ID: 8701818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.